Value through Innovation16 January 2013

Our Alliances in Research & Development

Complementing our in-house research & development efforts, our partnering activities focus on our strategic therapeutic areas. In our constant quest for "Value through Innovation", we are engaged in successful ongoing partnerships and are actively seeking new collaborations with external partners ranging from academic institutions to start-up companies or biotechnological enterprises. Strong alliance management functions at Boehringer Ingelheim ensure high-level commitment to successful execution of partnerships.

Extract of ongoing Alliances

Antibody technologies
Antitope Ltd.
Medarex, Inc.
MorphoSys AG
Xencor, Inc.
Biomarker
Caprion Proteomics, Inc.
Rules-Based Medicine, Inc.
Devices
Vectura Group plc
Disease related drug discovery
Axxam SpA
Evotec AG
Fragment based screening
Graffinity Pharmaceuticals GmbH
High throughput screening
Astex Therapeutics Ltd.
Evotec AG
Integrated electronic data handling
Biomax Informatics AG
Genomatix Software GmbH
Medicinal chemistry
Astex Therapeutics Ltd.
Evotec AG
Dalton Pharma Services
Protein formulation development
XstalBio Ltd.
Protein crystallography
Proteros biostructures GmbH
Protein scaffold technologies
Ablynx nv
NascaCell Technologies AG
RNAi-related target discovery
Cenix BioScience GmbH
Second generation biologics
Syntonix Pharmaceuticals, Inc.
Target validation
and compound profiling
Asterand plc
Kinaxo Biotechnologies GmbH
Therapeutic proteins
AbGenomics, Corp.
Evec, Inc.

Basic Research Institute

The Research Institute of Molecular Pathology

Our link to academia and basic research is represented by the IMP.

Research & Development

Research & Development

Oncology and white room

No flash player detected. For optimized usage of this website your browser should support shockwave flash. For downloading see Macromedia Flash Player